À¶Ý®ÊÓƵ

Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
À¶Ý®ÊÓƵ

Microbiome-Immune Interaction in Pulmonary Arterial Hypertension: What Have We Missed?

À¶Ý®ÊÓƵ

Microbiome-Immune Interaction in Pulmonary Arterial Hypertension: What Have We Missed? Research (Washington, D.C.) Zhou, X., Tian, W., Gu, S., Rabinovitch, M., Nicolls, M. R., Snyder, M. P. 2025; 8: 0669

Abstract

Pulmonary arterial hypertension (PAH) is a devastating disease characterized by perivascular inflammation, immune dysregulation, and vascular remodeling. Recent studies have unveiled a potential link between the gut microbiome and PAH pathogenesis, suggesting that microbial dysbiosis and increased intestinal permeability may contribute to the inflammatory pathology in PAH and ultimately disease progression. This perspective highlights the emerging evidence of the role of leaky gut in PAH, the interplay between microbiota-induced immune responses, and the activation of endogenous retroviruses like human endogenous retrovirus K. Understanding these complex interactions opens new interdisciplinary avenues for À¶Ý®ÊÓƵ and therapeutic interventions, potentially transforming PAH management through microbiome-targeted strategies.

View details for

View details for